Trial · NCT02501096
Participant flow45
How many started, completed or left each group, period by period.
1 to 20 of 45
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Phase 1b, Lenvatinib 24 mg/Day + Pembrolizumab 200 mg: RCC | 2 | |
| Overall Study | STARTED | Phase 1b, Lenvatinib 24 mg/Day + Pembrolizumab 200 mg: NSCLC | 1 | |
| Overall Study | STARTED | Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: EC | 124 | |
| Overall Study | STARTED | Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: RCC | 145 | |
| Overall Study | STARTED | Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: Melanoma | 21 | |
| Overall Study | STARTED | Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: NSCLC | 21 | |
| Overall Study | STARTED | Phase 1b and 2,Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: HNSCC | 22 | |
| Overall Study | STARTED | Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: UC | 20 | |
| Overall Study | STARTED | Phase1b and 2, Lenvatinib 20mg/Day+Pembrolizumab 200 mg: Leiomyosarcoma | 1 | |
| Overall Study | Phase 1b Participants Who Received, Lenvatinib 20 mg/Day + Pembrolizumab 200 mg. | Phase 1b, Lenvatinib 24 mg/Day + Pembrolizumab 200 mg: RCC | 0 | |
| Overall Study | Phase 1b Participants Who Received, Lenvatinib 20 mg/Day + Pembrolizumab 200 mg. | Phase 1b, Lenvatinib 24 mg/Day + Pembrolizumab 200 mg: NSCLC | 0 | |
| Overall Study | Phase 1b Participants Who Received, Lenvatinib 20 mg/Day + Pembrolizumab 200 mg. | Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: EC | 2 | |
| Overall Study | Phase 1b Participants Who Received, Lenvatinib 20 mg/Day + Pembrolizumab 200 mg. | Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: RCC | 6 | |
| Overall Study | Phase 1b Participants Who Received, Lenvatinib 20 mg/Day + Pembrolizumab 200 mg. | Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: Melanoma | 1 | |
| Overall Study | Phase 1b Participants Who Received, Lenvatinib 20 mg/Day + Pembrolizumab 200 mg. | Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: NSCLC | 1 | |
| Overall Study | Phase 1b Participants Who Received, Lenvatinib 20 mg/Day + Pembrolizumab 200 mg. | Phase 1b and 2,Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: HNSCC | 0 | |
| Overall Study | Phase 1b Participants Who Received, Lenvatinib 20 mg/Day + Pembrolizumab 200 mg. | Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: UC | 0 | |
| Overall Study | Phase 1b Participants Who Received, Lenvatinib 20 mg/Day + Pembrolizumab 200 mg. | Phase1b and 2, Lenvatinib 20mg/Day+Pembrolizumab 200 mg: Leiomyosarcoma | 0 | |
| Overall Study | Phase 2 Participants Who Received, Lenvatinib 20 mg/Day + Pembrolizumab 200 mg | Phase 1b, Lenvatinib 24 mg/Day + Pembrolizumab 200 mg: RCC | 0 | |
| Overall Study | Phase 2 Participants Who Received, Lenvatinib 20 mg/Day + Pembrolizumab 200 mg | Phase 1b, Lenvatinib 24 mg/Day + Pembrolizumab 200 mg: NSCLC | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02501096/flow